finance.yahoo.com ·
biostem technologies q1 earnings call 030601222
Topic context
This topic has been covered 336714 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedBioStem Technologies (biologics/wound care) pivots to hospital channel post-acquisition. Revenue mix shift to lower-margin hospital sales compresses gross margin from 97% to 61%. Company-specific margin squeeze; no commodity or supply-chain scarcity. Impact limited to BioStem's revenue and margin trajectory.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $6.1M, down from $10.1M Q4 but above guidance $5-6M
- Hospital sales $5.4M, physician office sales $772K
- Gross margin 61%, down from 97% prior quarter
- Full-year 2026 revenue guidance $25-29M
- Strategic shift to hospital market after late-January acquisition
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
fool.com
halozyme halo q1 2026 earnings transcript
economictimes.indiatimes.com
the rs 3 relief that wasnt why investors are dumping oil stocks after long awaited petrol diesel price hike
livemint.com